Revenues were $13.5bn for the first quarter ended 31 March 2013, a decrease of 9%, compared to $14.88bn for the same quarter of the previous year.
Pfizer chairman and chief executive officer Ian Read said, "We are clearly seeing the benefits of the investments we’ve been making in our innovative core, as evidenced by recent key product launches, including Eliquis, Xeljanz and various oncology products, as well as significant progress within our mid-to-late stage product pipeline, most notably palbociclib."
Revenues and expenses of Zoetis continue to be included in the 2013 financial guidance, except that adjusted and reported diluted EPS guidance excludes the earnings from the 19.8% divested interest effective 7 February 2013, according to the 2013 financial guidance.